Costs and Expenses of HERON THERAPEUTICS, INC. /DE/ from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
HERON THERAPEUTICS, INC. /DE/ quarterly and annual Costs and Expenses in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • HERON THERAPEUTICS, INC. /DE/ Costs and Expenses for the quarter ending 31 Dec 2025 was $29,431,000, a 12% increase year-over-year.
  • HERON THERAPEUTICS, INC. /DE/ Costs and Expenses for the twelve months ending 31 Dec 2025 was $116,095,000, a 0.91% decline year-over-year.
  • HERON THERAPEUTICS, INC. /DE/ annual Costs and Expenses for 2025 was $116,095,000, a 0.91% decline from 2024.
  • HERON THERAPEUTICS, INC. /DE/ annual Costs and Expenses for 2024 was $117,165,000, a 32% decline from 2023.
  • HERON THERAPEUTICS, INC. /DE/ annual Costs and Expenses for 2023 was $172,554,000, a 24% decline from 2022.
Source SEC data
View on sec.gov
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Change (%)
Costs and Expenses, Annual (USD)
Costs and Expenses, YoY Annual Change (%)

HERON THERAPEUTICS, INC. /DE/ Quarterly Costs and Expenses (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $116,095,000 $29,431,000 +$3,051,000 +12% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 $113,044,000 $30,392,000 +$2,582,000 +9.3% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $110,462,000 $28,980,000 -$2,971,000 -9.3% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $113,433,000 $27,292,000 -$3,732,000 -12% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $117,165,000 $26,380,000 -$8,188,000 -24% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 $125,353,000 $27,810,000 -$10,345,000 -27% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $135,698,000 $31,951,000 -$22,056,000 -41% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $157,754,000 $31,024,000 -$14,800,000 -32% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $172,554,000 $34,568,000 +$24,342,000 +238% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q3 2023 $148,212,000 $38,155,000 -$15,567,000 -29% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $163,779,000 $54,007,000 -$23,121,000 -30% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $186,900,000 $45,824,000 -$40,556,000 -47% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $227,456,000 $10,226,000 -$63,966,000 -86% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $291,422,000 $53,722,000 -$21,216,000 -28% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $312,638,000 $77,128,000 -$5,784,000 -7% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $318,422,000 $86,380,000 +$14,248,000 +20% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $304,174,000 $74,192,000 -$7,709,000 -9.4% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $311,883,000 $74,938,000 -$3,411,000 -4.4% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $315,294,000 $82,912,000 +$4,495,000 +5.7% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $310,799,000 $72,132,000 -$6,002,000 -7.7% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $316,801,000 $81,901,000 -$12,544,000 -13% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q3 2020 $329,345,000 $78,349,000 +$872,000 +1.1% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $328,473,000 $78,417,000 -$10,021,000 -11% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $338,494,000 $78,134,000 -$18,168,000 -19% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $356,662,000 $94,445,000 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $77,477,000 +$15,911,000 +26% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $88,438,000 +$32,308,000 +58% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $96,302,000 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q3 2018 $61,566,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $56,130,000 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019 2019 Q2

HERON THERAPEUTICS, INC. /DE/ Annual Costs and Expenses (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $116,095,000 -$1,070,000 -0.91% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $117,165,000 -$55,389,000 -32% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $172,554,000 -$54,902,000 -24% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 $227,456,000 -$76,718,000 -25% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $304,174,000 -$12,627,000 -4% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $316,801,000 -$39,861,000 -11% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2022 2021 FY
2019 $356,662,000 +$95,251,000 +36% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $261,411,000 +$36,086,000 +16% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
2017 $225,325,000 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.